Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PuriBlood Medical CoROCO:6847 +0.13%73 PS Ratio is 12.96 as of Jul. 24, 2026, which is 1% above its 10-year median of 12.86. GuruFocus rates ROCO:6847 with a GF Score™ of 73/100 and a GF Value™ of NT$65.92 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, PuriBlood Medical Co ranks worse than 87.5% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, PuriBlood Medical Co's share price is NT$75.00.
PuriBlood Medical Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$5.79. Hence, PuriBlood Medical Co's PS Ratio for today is 12.96.
The historical rank and industry rank for PuriBlood Medical Co's PS Ratio or its related term are showing as below:
ROCO:6847'
s PS Ratio Range Over the Past 10 Years
Min: 8.27 Med: 12.86 Max: 41.24
Current: 12.97
During the past 8 years, PuriBlood Medical Co's highest PS Ratio was 41.24. The lowest was 8.27. And the median was 12.86.
ROCO:6847's PS Ratio is ranked worse than 87.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.67
vs ROCO:6847: 12.97
PuriBlood Medical Co Ltd revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of PuriBlood Medical Co was -25.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -15.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 8.20% per year.
During the past 8 years, PuriBlood Medical Co's highest 3-Year average Revenue per Share Growth Rate was 199.40% per year. The lowest was -15.70% per year. And the median was 25.50% per year.
Back to Basics: PS Ratio
PuriBlood Medical Co (ROCO:6847) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
PuriBlood Medical Co PS Ratio Related Terms
PuriBlood Medical Co PS Ratio Historical Data
* Premium members only.
The historical data trend for PuriBlood Medical Co's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, PuriBlood Medical Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PuriBlood Medical Co PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, PuriBlood Medical Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where PuriBlood Medical Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
PuriBlood Medical Co's Share Price of today is NT$75.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PuriBlood Medical Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$5.79.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PuriBlood Medical Co (ROCO:6847) has a PS Ratio of 12.96 as of Jul. 24, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on PuriBlood Medical Co and its competitors. This is near median its historical median of 12.86. Over the past decade, PuriBlood Medical Co's PS Ratio has ranged from 8.27 to 41.24. According to the industry distribution chart, PuriBlood Medical Co ranks #175 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 87.5%.
Is PuriBlood Medical Co's PS Ratio too high?
PuriBlood Medical Co's current PS Ratio of 12.96 is near median its 10-year median of 12.86. Over the past 10 years, this metric has ranged from a low of 8.27 to a high of 41.24. The Medical Diagnostics & Research industry median PS Ratio is 2.67. PuriBlood Medical Co's value of 12.96 is 385.4% above this industry median. Based on the distribution chart, PuriBlood Medical Co ranks #175 out of 200 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, PuriBlood Medical Co has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PuriBlood Medical Co's PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, PuriBlood Medical Co ranks #175 out of 200 companies for PS Ratio. This places PuriBlood Medical Co in the lower half of its industry. The industry median PS Ratio is 2.67. PuriBlood Medical Co's value of 12.96 is 385.4% above this benchmark. Historically, PuriBlood Medical Co's own PS Ratio has ranged from 8.27 to 41.24 over the past decade. While the company's 10-year median is 12.86 vs. the industry median of 2.67, PuriBlood Medical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.67, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PuriBlood Medical Co's current PS Ratio of 12.96 is 385.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on PuriBlood Medical Co and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PuriBlood Medical Co's current PS Ratio is 12.96, which is near median its own 10-year median of 12.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PuriBlood Medical Co stock overvalued right now?
Based on GuruFocus' analysis, PuriBlood Medical Co (ROCO:6847) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$65.92, compared to a current price of NT$75.00 — trading 13.8% above its estimated fair value. The current PS Ratio is 12.96, which is near median its 10-year median of 12.86 and 385.4% above the Medical Diagnostics & Research industry median of 2.67. PuriBlood Medical Co's overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For PuriBlood Medical Co (ROCO:6847), the current PS Ratio is 12.96 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PuriBlood Medical Co (ROCO:6847) Overvalued in 2026?
Based on GuruFocus' analysis, PuriBlood Medical Co stock appears to be overvalued.
The current stock price of NT$75.00 is trading 13.8% above its estimated GF Value™ of NT$65.92.
GuruFocus considers PuriBlood Medical Co to be Modestly Overvalued.
Key valuation signals for ROCO:6847:
PS Ratio: 12.96 (near median its 10-year median of 12.86)
GF Value™: NT$65.92 vs. price of NT$75.00 (13.8% above fair value)
Industry Position: 385.4% above the Medical Diagnostics & Research median (#175 of 200)
No single metric tells the full story. See the ROCO:6847 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PuriBlood Medical Co Ltd is engaged in developing solutions for leukoreduction, cell separation, and anti-fouling materials. Its technology protects to supports living beings from medical devices to daily protection. The products of the company include Leukoreduction, Cell Separation, and P-tex.
73GF Score
Get the complete analysis for ROCO:6847
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6847 has been successfully added to your 
